Title :

The impact of anti-thymocyte globulin on the outcomes of patients with aml with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation

Author(s) :

Nagler, Arnon [Auteur]
Dholaria, Bhagirathbhai [Auteur]
Labopin, Myriam [Auteur]
Socie, Gerard [Auteur]
Huynh, Anne [Auteur]
Itala-Remes, Maija [Auteur]
Deconinck, Eric [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Cahn, Jean-Yves [Auteur]
Bourhis, Jean-Henri [Auteur]
Labussiere-Wallet, Helene [Auteur]
Chantepie, Sylvain [Auteur]
Esteve, Jordi [Auteur]
Savani, Bipin N. [Auteur]
Mohty, Mohamad [Auteur]

Journal title :

Leukemia

Abbreviated title :

Leukemia

Publication date :

2019-11-14

ISSN :

1476-5551

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Measurable residual disease (MRD) status pre-allogeneic hematopoietic cell transplantation (allo-HCT) has been shown to predict transplant outcomes. We investigated the effect of Anti-Thymocyte Globulin (ATG) on acute ...
Show more >Measurable residual disease (MRD) status pre-allogeneic hematopoietic cell transplantation (allo-HCT) has been shown to predict transplant outcomes. We investigated the effect of Anti-Thymocyte Globulin (ATG) on acute myelogenous leukemia (AML) relapse by pretransplant MRD status. AML patients undergoing allo-HCT in first complete remission from either a matched sibling or unrelated donor during the 2006-2017 period were selected. Outcomes of 1509 patients (MRD+-+-++Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-30T10:27:18Z